Trial design for evaluation of novel targeted therapies
- PMID: 19853899
- DOI: 10.1016/j.ygyno.2009.09.046
Trial design for evaluation of novel targeted therapies
Abstract
Objectives: The vast number of novel targeted therapies available for testing in the United States dictates that a more efficient system aimed at identifying promising agents for phase III testing needs to be developed. Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools are discussed.
Methods: Novel techniques for phase II trials were researched in the literature. Incorporation of surrogate endpoints and novel approaches were identified.
Results: Phase II trials are traditionally designed evaluating response rates compared to historical controls. In addition to identifying surrogates, novel approaches to phase II study design need to be tested. Incorporation of biomarkers into phase II trial design could allow for more accurate identification of patients who will benefit from targeted therapies. Tumor response as measured by anatomic imaging has been used to measure therapeutic efficacy in the era of cytotoxic drugs. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) however, has been used increasingly in the evaluation of biologic responses.
Conclusions: Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools should allow ineffective agents to be discarded and promising agents to undergo further investigation.
Published by Elsevier Inc.
Similar articles
-
Novel designs and end points for phase II clinical trials.Clin Cancer Res. 2009 Mar 15;15(6):1866-72. doi: 10.1158/1078-0432.CCR-08-2035. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276272 Review.
-
Phase II clinical trials in oncology: are we hitting the target?Expert Rev Anticancer Ther. 2010 Mar;10(3):427-38. doi: 10.1586/era.09.178. Expert Rev Anticancer Ther. 2010. PMID: 20214523 Review.
-
Improving the design of phase II trials of cytostatic anticancer agents.Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14. Contemp Clin Trials. 2007. PMID: 16843736 Review.
-
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1966-9. doi: 10.1158/1078-0432.CCR-05-1136. Clin Cancer Res. 2006. PMID: 16609005 Review.
-
[Methodological approaches of clinical studies with targeted therapies].Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575. Bull Cancer. 2008. PMID: 18304903 Review. French.
Cited by
-
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.J Pers Med. 2017 Jan 25;7(1):1. doi: 10.3390/jpm7010001. J Pers Med. 2017. PMID: 28125057 Free PMC article. Review.
-
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27. Neuro Oncol. 2011. PMID: 20980335 Free PMC article. Clinical Trial.
-
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.Oncologist. 2013;18(5):525-32. doi: 10.1634/theoncologist.2012-0434. Epub 2013 Apr 24. Oncologist. 2013. PMID: 23615698 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
